Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

GALDERMA GROUP AG

Healthcare US GALDY

42.94USD
0.00(0%)

Last update at 2026-06-22T20:00:00Z

Day Range

42.3843.03
LowHigh

52 Week Range

21.7042.93
LowHigh

Fundamentals

  • Previous Close 42.94
  • Market Cap45260.04M
  • Volume69551
  • P/E Ratio74.21
  • Dividend Yield0.23%
  • EBITDA1134.00M
  • Revenue TTM5241.00M
  • Revenue Per Share TTM4.45
  • Gross Profit TTM 3609.00M
  • Diluted EPS TTM0.52

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 638.00M 310.00M 11.00M -51.90000M -79.70000M
Minority interest - - 0.00000M 0.00000M 1.90M
Net income 613.00M 231.00M -57.00000M -98.50000M -154.30000M
Selling general administrative 2372.00M 2052.00M 1892.00M 1824.30M 1633.70M
Selling and marketing expenses - - - - -
Gross profit 3609.00M 3085.00M 2885.00M 2629.90M 2411.10M
Reconciled depreciation 323.00M 293.00M 276.00M 277.70M 253.10M
Ebit - - - - -
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 876.00M 678.00M 611.00M 406.00M 357.20M
Other operating expenses - - - - -
Interest expense 175.00M 356.00M 564.00M 398.40M 352.70M
Tax provision 26.00M 79.00M 68.00M 45.00M 4.60M
Interest income 13.00M 12.00M 6.00M 0.00000M 0.00000M
Net interest income -178.00000M -334.00000M -526.00000M -385.40000M -425.70000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 5241.00M 4440.00M 4117.00M 3823.90M 3445.00M
Total operating expenses 4365.00M 3762.00M 3506.00M 3417.90M 3087.80M
Cost of revenue 1632.00M 1355.00M 1232.00M 1194.00M 1033.90M
Total other income expense net - - - - -
Discontinued operations - - - - -
Net income from continuing ops 613.00M 231.00M -57.00000M -96.90000M -84.20000M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Total assets 13393.00M 12617.00M 12471.00M
Intangible assets 4639.00M 4828.00M 4922.00M
Earning assets - - -
Other current assets 1.00M - -
Total liab 5244.00M 4827.00M 7102.00M
Total stockholder equity 8149.00M 7790.00M 5369.00M
Deferred long term liab - - -
Other current liab - -1.00000M -
Common stock - - -
Capital stock 3.00M 3.00M 6.00M
Retained earnings 6347.00M 5676.00M -901.00000M
Other liab - - -
Good will 5129.00M 5129.00M 5129.00M
Other assets - - -
Cash 780.00M 457.00M 368.00M
Cash and equivalents - - -
Total current liabilities 2055.00M 1528.00M 1571.00M
Current deferred revenue - - -
Net debt 1826.00M 2186.00M 4419.00M
Short term debt - - -
Short long term debt 27.00M 6.00M 39.00M
Short long term debt total - - -
Other stockholder equity - - -
Property plant equipment - - -
Total current assets 2437.00M 1843.00M 1616.00M
Long term investments - - -
Net tangible assets - - -
Short term investments - - -
Net receivables 893.00M 754.00M 631.00M
Long term debt 2579.00M 2637.00M 4748.00M
Inventory 525.00M 403.00M 420.00M
Accounts payable 800.00M 571.00M 557.00M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other 36.00M 25.00M 20.00M
Deferred long term asset charges - - -
Non current assets total 10956.00M 10774.00M 10855.00M
Capital lease obligations 148.00M 117.00M 122.00M
Long term debt total - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -326.00000M -174.00000M -66.50000M -522.80000M
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings -293.00000M -2176.00000M -869.00000M -72.10000M 317.20M
Total cash from financing activities - - - - -
Change to operating activities - - - - -
Net income 613.00M 231.00M -57.00000M -98.50000M -154.30000M
Change in cash 323.00M 90.00M 134.00M -59.50000M -37.10000M
Begin period cash flow 457.00M 368.00M 234.00M 293.60M 330.70M
End period cash flow 780.00M 457.00M 368.00M 234.10M 293.60M
Total cash from operating activities 1185.00M 488.00M 165.00M 111.30M 195.70M
Issuance of capital stock 0.00000M 2166.00M 1011.00M 0.00000M 0.00000M
Depreciation 323.00M 293.00M 276.00M 277.70M 253.10M
Other cashflows from investing activities - - - - -
Dividends paid -41.00000M - - - -
Change to inventory -88.00000M -12.00000M 31.00M -127.40000M -52.80000M
Change to account receivables - - - - -
Sale purchase of stock -363.00000M -15.00000M 0.00000M - -
Other cashflows from financing activities - - - - -
Change to netincome - - - - -
Capital expenditures 154.00M 275.00M 153.00M 159.50M 128.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 194.00M -148.00000M -35.00000M -78.50000M 25.60M
Stock based compensation 64.00M 68.00M 0.00000M - -
Other non cash items 194.00M 329.00M 527.00M 362.60M 340.70M
Free cash flow 1031.00M 213.00M 12.00M -48.20000M 67.70M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.16 1.02% 15.47 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

GALDERMA GROUP AG

Zählerweg 10, Zug, Switzerland, 6300

Key Executives

Name Title Year Born
Dr. Flemming Ornskov M.B.A., M.D., M.P.H. CEO & Director 1958
Mr. Thomas J. W. Dittrich Chief Financial Officer 1964
Mr. Adrian Murphy Head of Global Operations 1970
Mr. Emil Ivanov Head of Strategy, Investor Relations & ESG NA
Ms. Nakisa Serry J.D., MBA General Counsel, Chief Compliance Officer & Interim CHRO NA
Mr. Christian Marcoux Chief Communications Officer NA
Ms. Desislava Lazarova M.D. Global Head of Customer Education & Training NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions